Search

Your search keyword '"Canonica, Giorgio"' showing total 48 results
Start Over Author "Canonica, Giorgio" Journal allergy
48 results on '"Canonica, Giorgio"'

2. Statistical advice provided by ChatGPT regarding an accepted article in Allergy.

Author

Ordak, Michal, Canonica, Giorgio Walter, Paoletti, Giovanni, Brussino, Liusa, Carvalho, Daniela, and Di Bona, Danilo

Subjects
*CHATGPT, *SUBLINGUAL immunotherapy, *HOUSE dust mites, *ALLERGIES, *ADVICE
Abstract

The article discusses the use of artificial intelligence (AI) tools, specifically ChatGPT, in providing statistical advice for scientific research. While AI can be helpful in solving narrow problems, there are concerns about relying too heavily on AI for health advice, as it can lead to misinformation and risks to our health. The article presents a study that analyzed ChatGPT's statistical skills in the field of allergology and found limitations in its ability to provide accurate and reliable answers. The authors emphasize the importance of human oversight and the need for researchers to familiarize themselves with statistical recommendations. They also suggest increasing the use of statistical reviewers by biomedical journal editors to improve the quality of published research. [Extracted from the article]

Published
2024
Full Text
View/download PDF

4. Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both

Author

Pfeffer, Paul E., primary, Ali, Nasloon, additional, Murray, Ruth, additional, Ulrik, Charlotte, additional, Tran, Trung N., additional, Maspero, Jorge, additional, Peters, Matthew, additional, Christoff, George C., additional, Sadatsafavi, Mohsen, additional, Torres‐Duque, Carlos A., additional, Altraja, Alan, additional, Lehtimäki, Lauri, additional, Papadopoulos, Nikolaos G., additional, Salvi, Sundeep, additional, Costello, Richard W., additional, Cushen, Breda, additional, Heffler, Enrico, additional, Iwanaga, Takashi, additional, Al‐Ahmad, Mona, additional, Larenas‐Linnemann, Désirée, additional, Kuna, Piotr, additional, Fonseca, João A., additional, Al‐Lehebi, Riyad, additional, Rhee, Chin Kook, additional, Perez‐de‐Llano, Luis, additional, Perng Steve, Diahn‐Warng, additional, Mahboub, Bassam, additional, Wang, Eileen, additional, Goh, Celine, additional, Lyu, Juntao, additional, Newell, Anthony, additional, Alacqua, Marianna, additional, Belevskiy, Andrey S., additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjornsdottir, Unnur, additional, Bourdin, Arnaud, additional, Bulow, Anna von, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Cosio, Borja G., additional, Dorscheid, Delbert R., additional, Muñoz‐Esquerre, Mariana, additional, FitzGerald, J. Mark, additional, Gil, Esther Garcia, additional, Gibson, Peter G., additional, Heaney, Liam G., additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Jackson, David J., additional, Koh, Mariko Siyue, additional, Ko, Hsin‐Kuo Bruce, additional, Lee, Jae Ha, additional, Lehmann, Sverre, additional, Chaves Loureiro, Cláudia, additional, Lúðvíksdóttir, Dóra, additional, Menzies‐Gow, Andrew N., additional, Mitchell, Patrick, additional, Papaioannou, Andriana I., additional, Popov, Todor A., additional, Porsbjerg, Celeste M., additional, Salameh, Laila, additional, Sirena, Concetta, additional, Taillé, Camille, additional, Taube, Christian, additional, Tohda, Yuji, additional, Wechsler, Michael E., additional, and Price, David B., additional

Published
2023
Full Text
View/download PDF

7. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens

Author

Potapova, Ekaterina, primary, Bordas‐Le Floch, Véronique, additional, Schlederer, Thomas, additional, Vrtala, Susanne, additional, Huang, Huey‐Jy, additional, Canonica, Giorgio W., additional, Valenta, Rudolf, additional, Matricardi, Paolo M., additional, and Mascarell, Laurent, additional

Published
2022
Full Text
View/download PDF

9. Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”

Author

Paoletti, Giovanni, primary, Di Bona, Danilo, additional, Chu, Derek K., additional, Firinu, Davide, additional, Heffler, Enrico, additional, Agache, Ioana, additional, Jutel, Marek, additional, Klimek, Ludger, additional, Pfaar, Oliver, additional, Mösges, Ralph, additional, DunnGalvin, Audrey, additional, Genuneit, Jon, additional, Hoffmann, Hans Jürgen, additional, and Canonica, Giorgio Walter, additional

Published
2021
Full Text
View/download PDF

13. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Author

Agache, Ioana, primary, Song, Yang, additional, Alonso‐Coello, Pablo, additional, Vogel, Yasmin, additional, Rocha, Claudio, additional, Solà, Ivan, additional, Santero, Marilina, additional, Akdis, Cezmi A., additional, Akdis, Mubeccel, additional, Canonica, Giorgio Walter, additional, Chivato, Tomas, additional, del Giacco, Stefano, additional, Eiwegger, Thomas, additional, Fokkens, Wytske, additional, Georgalas, Christos, additional, Gevaert, Philippe, additional, Hopkins, Claire, additional, Klimek, Ludger, additional, Lund, Valerie, additional, Naclerio, Robert, additional, O'Mahony, Liam, additional, Palkonen, Susanna, additional, Pfaar, Oliver, additional, Schwarze, Jürgen, additional, Soyka, Michael B., additional, Wang, De Yun, additional, Zhang, Luo, additional, Canelo‐Aybar, Carlos, additional, Palomares, Oscar, additional, and Jutel, Marek, additional

Published
2021
Full Text
View/download PDF

14. COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Author

Pfaar, Oliver, primary, Klimek, Ludger, additional, Jutel, Marek, additional, Akdis, Cezmi A., additional, Bousquet, Jean, additional, Breiteneder, Heimo, additional, Chinthrajah, Sharon, additional, Diamant, Zuzana, additional, Eiwegger, Thomas, additional, Fokkens, Wytske J., additional, Fritsch, Hans‐Walter, additional, Nadeau, Kari C., additional, O’Hehir, Robyn E., additional, O’Mahony, Liam, additional, Rief, Winfried, additional, Sampath, Vanitha, additional, Schedlowski, Manfred, additional, Torres, María José, additional, Traidl‐Hoffmann, Claudia, additional, Wang, De Yun, additional, Zhang, Luo, additional, Bonini, Matteo, additional, Brehler, Randolf, additional, Brough, Helen Annaruth, additional, Chivato, Tomás, additional, Del Giacco, Stefano R., additional, Dramburg, Stephanie, additional, Gawlik, Radoslaw, additional, Gelincik, Aslı, additional, Hoffmann‐Sommergruber, Karin, additional, Hox, Valerie, additional, Knol, Edward F., additional, Lauerma, Antti, additional, Matricardi, Paolo M., additional, Mortz, Charlotte G., additional, Ollert, Markus, additional, Palomares, Oscar, additional, Riggioni, Carmen, additional, Schwarze, Jürgen, additional, Skypala, Isabel, additional, Untersmayr, Eva, additional, Walusiak‐Skorupa, Jolanta, additional, Ansotegui, Ignacio J., additional, Bachert, Claus, additional, Bedbrook, Anna, additional, Bosnic‐Anticevich, Sinthia, additional, Brussino, Luisa, additional, Canonica, Giorgio Walter, additional, Cardona, Victoria, additional, Carreiro‐Martins, Pedro, additional, Cruz, Alvaro A., additional, Czarlewski, Wienczyslawa, additional, Fonseca, João A., additional, Gotua, Maia, additional, Haahtela, Tari, additional, Ivancevich, Juan Carlos, additional, Kuna, Piotr, additional, Kvedariene, Violeta, additional, Larenas‐Linnemann, Désirée Erlinda, additional, Abdul Latiff, Amir Hamzah, additional, Mäkelä, Mika, additional, Morais‐Almeida, Mário, additional, Mullol, Joaquim, additional, Naclerio, Robert, additional, Ohta, Ken, additional, Okamoto, Yoshitaka, additional, Onorato, Gabrielle L., additional, Papadopoulos, Nikolaos G., additional, Patella, Vincenzo, additional, Regateiro, Frederico S., additional, Samoliński, Bolesław, additional, Suppli Ulrik, Charlotte, additional, Toppila‐Salmi, Sanna, additional, Valiulis, Arunas, additional, Ventura, Maria‐Teresa, additional, Yorgancioglu, Arzu, additional, Zuberbier, Torsten, additional, and Agache, Ioana, additional

Published
2021
Full Text
View/download PDF

15. What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders.

Author

Maggi, Enrico, Azzarone, Bruno Giuseppe, Canonica, Giorgio Walter, and Moretta, Lorenzo

Subjects
SARS-CoV-2, CORONAVIRUS diseases, COVID-19, VIRUS diseases
Abstract

The coronavirus disease 2019 (COVID‐19) pandemic started in March 2020 and caused over 5 million confirmed deaths worldwide as far August 2021. We have been recently overwhelmed by a wide literature on how the immune system recognizes severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and contributes to COVID‐19 pathogenesis. Although originally considered a respiratory viral disease, COVID‐19 is now recognized as a far more complex, multi‐organ‐, immuno‐mediated‐, and mostly heterogeneous disorder. Though efficient innate and adaptive immunity may control infection, when the patient fails to mount an adequate immune response at the start, or in advanced disease, a high innate‐induced inflammation can lead to different clinical outcomes through heterogeneous compensatory mechanisms. The variability of viral load and persistence, the genetic alterations of virus‐driven receptors/signaling pathways and the plasticity of innate and adaptive responses may all account for the extreme heterogeneity of pathogenesis and clinical patterns. As recently applied to some inflammatory disorders as asthma, rhinosinusitis with polyposis, and atopic dermatitis, herein we suggest defining different endo‐types and the related phenotypes along COVID‐19. Patients should be stratified for evolving symptoms and tightly monitored for surrogate biomarkers of innate and adaptive immunity. This would allow to preventively identify each endo‐type (and its related phenotype) and to treat patients precisely with agents targeting pathogenic mechanisms. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

Author

Incorvaia, Cristoforo, primary, Al‐Ahmad, Mona, additional, Ansotegui, Ignacio J., additional, Arasi, Stefania, additional, Bachert, Claus, additional, Bos, Catherine, additional, Bousquet, Jean, additional, Bozek, Andrzéj, additional, Caimmi, Davide, additional, Calderón, Moises A., additional, Casale, Thomas, additional, Custovic, Adnan, additional, De Blay, Frédéric, additional, Demoly, Pascal, additional, Devillier, Philippe, additional, Didier, Alain, additional, Fiocchi, Alessandro, additional, Fox, Adam T., additional, Gevaert, Philippe, additional, Gomez, Maximiliano, additional, Heffler, Enrico, additional, Ilina, Natalia, additional, Irani, Carla, additional, Jutel, Marek, additional, Karagiannis, Efstrathios, additional, Klimek, Ludger, additional, Kuna, Piotr, additional, O'Hehir, Robin, additional, Kurbacheva, Oxana, additional, Matricardi, Paolo M., additional, Morais‐Almeida, Mario, additional, Mosges, Ralph, additional, Novak, Natalija, additional, Okamoto, Yoshitaka, additional, Panzner, Petr, additional, Papadopoulos, Nikolaos G., additional, Park, Hae‐Sim, additional, Passalacqua, Giovanni, additional, Pawankar, Ruby, additional, Pfaar, Oliver, additional, Schmid‐Grendelmeier, Peter, additional, Scurati, Silvia, additional, Tortajada‐Girbés, Miguel, additional, Vidal, Carmen, additional, Virchow, J. Christian, additional, Wahn, Ulrich, additional, Worm, Margitta, additional, Zieglmayer, Petra, additional, and Canonica, Giorgio W., additional

Published
2020
Full Text
View/download PDF

17. ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)

Author

Bousquet, Jean, primary, Jutel, Marek, additional, Akdis, Cezmi A., additional, Klimek, Ludger, additional, Pfaar, Oliver, additional, Nadeau, Kari C., additional, Eiwegger, Thomas, additional, Bedbrook, Anna, additional, Ansotegui, Ignacio J., additional, Anto, Josep M., additional, Bachert, Claus, additional, Bateman, Eric D., additional, Bennoor, Kazi S., additional, Berghea, Elena Camelia, additional, Bergmann, Karl‐Christian, additional, Blain, Hubert, additional, Bonini, Mateo, additional, Bosnic‐Anticevich, Sinthia, additional, Boulet, Louis‐Philippe, additional, Brussino, Luisa, additional, Buhl, Roland, additional, Camargos, Paulo, additional, Canonica, Giorgio Walter, additional, Cardona, Victoria, additional, Casale, Thomas, additional, Chinthrajah, Sharon, additional, Akdis, Mübeccel, additional, Chivato, Tomas, additional, Christoff, George, additional, Cruz, Alvaro A., additional, Czarlewski, Wienczyslawa, additional, Del Giacco, Stefano, additional, Du, Hui, additional, El‐Gamal, Yehia, additional, Fokkens, Wytske J., additional, Fonseca, Joao A., additional, Gao, Yadong, additional, Gaga, Mina, additional, Gemicioglu, Bilun, additional, Gotua, Maia, additional, Haahtela, Tari, additional, Halpin, David, additional, Hamelmann, Eckard, additional, Hoffmann‐Sommergruber, Karin, additional, Humbert, Marc, additional, Ilina, Nataliya, additional, Ivancevich, Juan‐Carlos, additional, Joos, Guy, additional, Khaitov, Musa, additional, Kirenga, Bruce, additional, Knol, Edward F., additional, Ko, Fanny W., additional, Koskinen, Seppo, additional, Kowalski, Marek L., additional, Kraxner, Helga, additional, Kudlay, Dmitry, additional, Kuna, Piotr, additional, Kupczyk, Maciej, additional, Kvedariene, Violeta, additional, Abdul Latiff, Amir H., additional, Le, Lan T., additional, Levin, Michael, additional, Larenas‐Linnemann, Desiree, additional, Louis, Renaud, additional, Masjedi, Mohammad R., additional, Melén, Erik, additional, Mihaltan, Florin, additional, Milenkovic, Branislava, additional, Mohammad, Yousser, additional, Morais‐Almeida, Mario, additional, Mullol, Joaquim, additional, Namazova, Leyla, additional, Neffen, Hugo, additional, Nunes, Elisabete, additional, O’Byrne, Paul, additional, O’Hehir, Robyn, additional, O’Mahony, Liam, additional, Ohta, Ken, additional, Okamoto, Yoshitaka, additional, Onorato, Gabrielle L., additional, Panzner, Petr, additional, Papadopoulos, Nikos G., additional, Passalacqua, Gianni, additional, Patella, Vincenzo, additional, Pawankar, Ruby, additional, Pham‐Thi, Nhân, additional, Pigearias, Bernard, additional, Popov, Todor A., additional, Puggioni, Francesca, additional, Regateiro, Frederico S., additional, Rolla, Giovanni, additional, Rottem, Menachem, additional, Samolinski, Boleslaw, additional, Sastre, Joaquin, additional, Schwarze, Jurgen, additional, Sheikh, Aziz, additional, Scichilone, Nicola, additional, Soto‐Quiros, Manuel, additional, Soto‐Martinez, Manuel, additional, Sova, Milan, additional, Nicola, Stefania, additional, Stelmach, Rafael, additional, Suppli‐Ulrik, Charlotte, additional, Taborda‐Barata, Luis, additional, To, Teresa, additional, Tomazic, Peter‐Valentin, additional, Toppila‐Salmi, Sanna, additional, Tsiligianni, Ioanna, additional, Usmani, Omar, additional, Valiulis, Arunas, additional, Ventura, Maria Teresa, additional, Viegi, Giovanni, additional, Vontetsianos, Theodor, additional, Wang, De Yun, additional, Williams, Sian, additional, Wong, Gary W. K., additional, Yorgancioglu, Arzu, additional, Zernotti, Mario, additional, Zidarn, Mihaela, additional, Zuberbier, Torsten, additional, and Agache, Ioana, additional

Published
2020
Full Text
View/download PDF

18. EAACI Biologicals Guidelines—Recommendations for severe asthma

Author

Agache, Ioana, primary, Akdis, Cezmi A., additional, Akdis, Mubeccel, additional, Canonica, Giorgio Walter, additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Chu, Derek K., additional, Del Giacco, Stefano, additional, Eiwegger, Thomas, additional, Flood, Breda, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Hernández‐Martín, Irene, additional, Knibb, Rebeca, additional, Mäkelä, Mika, additional, Nair, Parameswaran, additional, O’Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Pfaar, Oliver, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Schwarze, Jurgen, additional, Palomares, Oscar, additional, and Jutel, Marek, additional

Published
2020
Full Text
View/download PDF

20. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Author

Agache, Ioana, primary, Rocha, Claudio, additional, Beltran, Jessica, additional, Song, Yang, additional, Posso, Margarita, additional, Solà, Ivan, additional, Alonso‐Coello, Pablo, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Canonica, Giorgio W., additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Del Giacco, Stefano, additional, Eiwegger, Thomas, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Mäkelä, Mika, additional, Martín, Irene Hernández, additional, Nair, Parameswaran, additional, O'Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Schwarze, Jurgen, additional, Canelo‐Aybar, Carlos, additional, Palomares, Oscar, additional, and Jutel, Marek, additional

Published
2020
Full Text
View/download PDF

21. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

Author

Agache, Ioana, primary, Song, Yang, additional, Rocha, Claudio, additional, Beltran, Jessica, additional, Posso, Margarita, additional, Steiner, Corinna, additional, Alonso‐Coello, Pablo, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Canonica, Giorgio Walter, additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Giacco, Stefano, additional, Eiwegger, Thomas, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Mäkelä, Mika, additional, Martín, Irene Hernández, additional, Nair, Parameswaran, additional, O'Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Schwarze, Jurgen, additional, Canelo‐Aybar, Carlos, additional, Palomares, Oscar, additional, and Jutel, Marek, additional

Published
2020
Full Text
View/download PDF

23. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Author

Agache, Ioana, primary, Beltran, Jessica, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Canelo‐Aybar, Carlos, additional, Canonica, Giorgio Walter, additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Del Giacco, Stefano, additional, Eiwegger, Thomas, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Mäkelä, Mika, additional, Hernández‐Martín, Irene, additional, Nair, Parameswaran, additional, O'Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Posso, Margarita, additional, Rocha, Claudio, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Song, Yang, additional, Steiner, Corinna, additional, Schwarze, Jurgen, additional, Alonso‐Coello, Pablo, additional, Palomares, Oscar, additional, and Jutel, Marek, additional

Published
2020
Full Text
View/download PDF

24. The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life

Author

Bagnasco, Diego, primary, Massolo, Alessandro, additional, Bonavia, Marco, additional, Brussino, Luisa, additional, Bucca, Caterina, additional, Caminati, Marco, additional, Canonica, Giorgio Walter, additional, Caruso, Cristiano, additional, D’Amato, Maria, additional, De Ferrari, Laura, additional, Guida, Giuseppe, additional, Heffler, Enrico, additional, Lombardi, Carlo, additional, Menzella, Francesco, additional, Milanese, Manlio, additional, Paoletti, Giovanni, additional, Riccio, Anna Maria, additional, Rolla, Giovanni, additional, Senna, Gianenrico, additional, Testino, Elisa, additional, and Passalacqua, Giovanni, additional

Published
2020
Full Text
View/download PDF

26. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.

Author

Canonica, Giorgio Walter, Harrison, Tim W., Chanez, Pascal, Menzella, Francesco, Louis, Renaud, Cosio, Borja G., Lugogo, Njira L., Mohan, Arjun, Burden, Annie, and Garcia Gil, Esther

Subjects
*NASAL polyps, *ASTHMA, *ASTHMATICS, *FEVER, *SYMPTOMS, *DIAGNOSIS
Abstract

Background: Clinically meaningful improvement in the Sino‐Nasal Outcome Test‐22 (SNOT‐22) was observed in patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated with benralizumab in the ANDHI trial. A post hoc assessment of the effects of benralizumab on SNOT‐22 response and asthma efficacy measures in these patients was conducted for further characterization of the efficacy and safety of benralizumab for patients with severe asthma and NP. Methods: Adults with severe, eosinophilic asthma who had experienced ≥2 prior‐year exacerbations despite high‐dosage inhaled corticosteroid plus additional controller[s] were randomized to 24 weeks of benralizumab or placebo. Patients with physician‐diagnosed chronic rhinosinusitis with NP of any severity ongoing at baseline who consented to participate were included in the current ANDHI NP substudy population. Effect on NP symptoms was assessed by the SNOT‐22, with an improvement of at least 8.9 defined as clinically significant (responder). Effects on chronic asthma outcomes were assessed by means of annualized asthma exacerbation rate (AER), St. George's Respiratory Questionnaire (SGRQ) total score, forced expiratory volume in one second (FEV1), and Asthma Control Questionnaire‐6 (ACQ‐6). All p‐values were nominal. Results: Of the ANDHI population (n = 656), 23% (n = 153) participated in the NP substudy (n = 96 benralizumab; n = 57 placebo). Patients were 50% female, with mean age of 53 years, had prior‐year AER = 3.3; mean pre‐bronchodilator FEV1 = 55% predicted; and median blood eosinophil count ​= 510 cells/µl. For patients with high baseline SNOT‐22 scores (>30), benralizumab treatment improved symptoms of NP as measured by SNOT‐22 from baseline to Week 24 compared with placebo (Week 24: −10.44 [p =.0176]). Percentage of responders to SNOT‐22 was greater for benralizumab vs. placebo (71.3% vs. 45.5%; p =.0036), and effect was enhanced for patients with high baseline SNOT‐22 scores (>30). A 69% reduction vs. placebo in annualized AER (0.77 vs. 2.47; p <.0001) and greater clinically meaningful improvements from baseline in SGRQ total score (−16.7), FEV1 (+0.32 L), and ACQ‐6 (–0.88) were observed (p <.0001). Benralizumab was well‐tolerated. Frequency of adverse events (AEs) was similar for benralizumab (76.0%) and placebo (73.7%) groups. Most common AEs (frequency ≥5%) reported at a greater frequency in benralizumab vs. placebo included headache, sinusitis, pyrexia, and influenza. Conclusions: These substudy data from ANDHI demonstrated the efficacy profile of benralizumab for patients with severe, eosinophilic asthma and NP, with improvement in SNOT‐22 and asthma outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. EUFOREA consensus on biologics for CRSwNP with or without asthma

Author

Fokkens, Wytske J., primary, Lund, Valerie, additional, Bachert, Claus, additional, Mullol, Joaquim, additional, Bjermer, Leif, additional, Bousquet, Jean, additional, Canonica, Giorgio W., additional, Deneyer, Lauren, additional, Desrosiers, Martin, additional, Diamant, Zuzana, additional, Han, Joseph, additional, Heffler, Enrico, additional, Hopkins, Claire, additional, Jankowski, Roger, additional, Joos, Guy, additional, Knill, Andrew, additional, Lee, Jivianne, additional, Lee, Stella E., additional, Mariën, Gert, additional, Pugin, Benoit, additional, Senior, Brent, additional, Seys, Sven F., additional, and Hellings, Peter W., additional

Published
2019
Full Text
View/download PDF

29. ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”

Author

Bosnic‐Anticevich, Sinthia, primary, Costa, Elisio, additional, Menditto, Enrica, additional, Lourenço, Olga, additional, Novellino, Ettore, additional, Bialek, Slawomir, additional, Briedis, Vitalis, additional, Buonaiuto, Roland, additional, Chrystyn, Henry, additional, Cvetkovski, Biljana, additional, Di Capua, Stefania, additional, Kritikos, Vicky, additional, Mair, Alpana, additional, Orlando, Valentina, additional, Paulino, Ema, additional, Salimäki, Johanna, additional, Söderlund, Rojin, additional, Tan, Rachel, additional, Williams, Dennis M., additional, Wroczynski, Piotr, additional, Agache, Ioana, additional, Ansotegui, Ignacio J., additional, Anto, Josep M., additional, Bedbrook, Anna, additional, Bachert, Claus, additional, Bewick, Mike, additional, Bindslev‐Jensen, Carsten, additional, Brozek, Jan L., additional, Canonica, Giorgio Walter, additional, Cardona, Victoria, additional, Carr, Warner, additional, Casale, Thomas B., additional, Chavannes, Niels H., additional, Correia de Sousa, Jaime, additional, Cruz, Alvaro A., additional, Czarlewski, Wienczyslawa, additional, De Carlo, Giuseppe, additional, Demoly, Pascal, additional, Devillier, Philippe, additional, Dykewicz, Mark S., additional, Gaga, Mina, additional, El‐Gamal, Yehia, additional, Fonseca, João, additional, Fokkens, Wytske J., additional, Guzmán, Maria Antonieta, additional, Haahtela, Tari, additional, Hellings, Peter W., additional, Illario, Maddalena, additional, Ivancevich, Juan Carlos, additional, Just, Jocelyne, additional, Kaidashev, Igor, additional, Khaitov, Musa, additional, Khaltaev, Nikolai, additional, Keil, Thomas, additional, Klimek, Ludger, additional, Kowalski, Marek L., additional, Kuna, Piotr, additional, Kvedariene, Violeta, additional, Larenas‐Linnemann, Désirée E., additional, Laune, Daniel, additional, Le, Lan T. T., additional, Lodrup Carlsen, Karin C., additional, Mahboub, Bassam, additional, Maier, Dieter, additional, Malva, Joao, additional, Manning, Patrick J., additional, Morais‐Almeida, Mário, additional, Mösges, Ralph, additional, Mullol, Joaquim, additional, Münter, Lars, additional, Murray, Ruth, additional, Naclerio, Robert, additional, Namazova‐Baranova, Leyla, additional, Nekam, Kristof, additional, Nyembue, Tshipukane Dieudonné, additional, Okubo, Kimi, additional, O'Hehir, Robyn E., additional, Ohta, Ken, additional, Okamoto, Yoshitaka, additional, Onorato, Gabrielle L., additional, Palkonen, Susanna, additional, Panzner, Petr, additional, Papadopoulos, Nikolaos G., additional, Park, Hae‐Sim, additional, Pawankar, Ruby, additional, Pfaar, Oliver, additional, Phillips, Jim, additional, Plavec, Davor, additional, Popov, Todor A., additional, Potter, Paul C., additional, Prokopakis, Emmanuel P., additional, Roller‐Wirnsberger, Regina E., additional, Rottem, Menachem, additional, Ryan, Dermot, additional, Samolinski, Bolesław, additional, Sanchez‐Borges, Mario, additional, Schunemann, Holger J., additional, Sheikh, Aziz, additional, Sisul, Juan Carlos, additional, Somekh, David, additional, Stellato, Cristiana, additional, To, Teresa, additional, Todo‐Bom, Ana Maria, additional, Tomazic, Peter Valentin, additional, Toppila‐Salmi, Sanna, additional, Valero, Antonio, additional, Valiulis, Arunas, additional, Valovirta, Errka, additional, Ventura, Maria Teresa, additional, Wagenmann, Martin, additional, Wallace, Dana, additional, Waserman, Susan, additional, Wickman, Magnus, additional, Yiallouros, Panayiotis K., additional, Yorgancioglu, Arzu, additional, Yusuf, Osman M., additional, Zar, Heather J., additional, Zernotti, Mario E., additional, Zhang, Luo, additional, Zidarn, Mihaela, additional, Zuberbier, Torsten, additional, and Bousquet, Jean, additional

Published
2019
Full Text
View/download PDF

30. COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments.

Author

Heffler, Enrico, Detoraki, Aikaterini, Contoli, Marco, Papi, Alberto, Paoletti, Giovanni, Malipiero, Giacomo, Brussino, Luisa, Crimi, Claudia, Morrone, Daniela, Padovani, Marianna, Guida, Giuseppe, Gerli, Alberto Giovanni, Centanni, Stefano, Senna, Gianenrico, Paggiaro, Pierluigi, Blasi, Francesco, and Canonica, Giorgio Walter

Subjects
TYPE 2 diabetes, COVID-19, SARS-CoV-2
Abstract

All centres have been contacted and inquired to report confirmed or highly suspect cases of COVID-19 (ie, patients with symptoms, laboratory findings and lung imaging typical of COVID-19 but without access to nasopharyngeal or oropharyngeal swab specimens because of clinical contingencies/emergency) among their cohorts of severe asthma. The total number of patients with severe asthma for each single region is reported under the each region name gl Nine (34.6%) infected patients experienced worsening of asthma during the COVID-19 symptomatic period; four of them needed a short course of oral corticosteroids for controlling asthma exacerbation symptoms. This is in line with the under-reported asthma cases among patients with COVID-19 patients.3 The COVID-19 related mortality rate in our cohort of patients was 7.7%, lower than in the general population (14.5% in Italy1). Since the end of February 2020, Italy, first non-Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200 000 confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected subjects, resulting in more than 34 000 deaths (data updated to June 19th, 20201). [Extracted from the article]

Published
2021
Full Text
View/download PDF

31. EAACI Biologicals Guidelines—Recommendations for severe asthma.

Author

Agache, Ioana, Akdis, Cezmi A., Akdis, Mubeccel, Canonica, Giorgio Walter, Casale, Thomas, Chivato, Tomas, Corren, Jonathan, Chu, Derek K., Del Giacco, Stefano, Eiwegger, Thomas, Flood, Breda, Firinu, Davide, Gern, James E., Hamelmann, Eckard, Hanania, Nicola, Hernández‐Martín, Irene, Knibb, Rebeca, Mäkelä, Mika, Nair, Parameswaran, and O'Mahony, Liam

Subjects
BIOLOGICALS, ASTHMA, GUIDELINES, TREATMENT duration
Abstract

Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based) and its cost‐effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement.

Author

Pfaar, Oliver, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi, Bousquet, Jean, Akdis, Mübeccel, Bachert, Claus, Agache, Ioana, Ansotegui, Ignacio, Bedbrook, Anna, Bosnic‐Anticevich, Sinthia, Canonica, Giorgio W., Chivato, Tomas, Cruz, Alvaro A., Czarlewski, Wienia, Del Giacco, Stefano, Du, Hui, Fonseca, Joao A., Gao, Yadong, and Haahtela, Tari

Subjects
COVID-19 pandemic, ALLERGIC conjunctivitis, COVID-19, MERS coronavirus, ALLERGENS
Abstract

Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement Keywords: allergy treatment; immunotherapy clinical; immunotherapy vaccines and mechanisms EN allergy treatment immunotherapy clinical immunotherapy vaccines and mechanisms 1546 1554 9 07/14/20 20200701 NES 200701 INTRODUCTION The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy diagnosis and treatment is performed. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations how to perform treatment during the pandemic and in SARS-CoV-2 infected patients. AIT can also be continued as usual in patients without clinical symptoms and signs of COVID-19 or other infections and without a history of exposure to SARS-CoV-2 or contact to COVID-19 confirmed individuals within the past 14 days. [Extracted from the article]

Published
2020
Full Text
View/download PDF

33. 30 years of sublingual immunotherapy.

Author

Passalacqua, Giovanni, Bagnasco, Diego, and Canonica, Giorgio Walter

Subjects
SUBLINGUAL immunotherapy, RESPIRATORY allergy, FOOD allergy, ATOPIC dermatitis, CLINICAL trials, HISTORY of medicine, TREATMENT effectiveness
Abstract

Allergen Immunotherapy (AIT) was introduced in clinical practice on an empirical basis more than 100 years ago. Since the first attempts, AIT was administered subcutaneously. Indeed, other routes of administration were proposed and studied, in particular to improve the safety, but only the sublingual route (SLIT) achieved a credibility based on evidence and was then accepted as a viable "alternative" option to the subcutaneous route. SLIT was largely used in clinical trials and clinical practice in this last 30 years. Thus, a large amount of data is available, coming from either controlled trials and postmarketing surveillance studies. It is clear that SLIT is overall effective, but it is also clear that the efficacy is not "class‐related," as derived from meta‐analyses, but restricted to each specific product. The 30‐year lasting use of SLIT allowed to clarify many clinical aspects, such as efficacy, safety, use in asthma, regimens of administration, and optimal doses. In parallel, the mechanisms of action of AIT were elucidated, and new indications were proposed (eg food allergy, atopic dermatitis). In addition, the introduction of molecular‐based diagnosis, allowed to better refine the prescription of SLIT, based on specific sensitization profiles. The present article will describe the origin and evolution of SLIT for respiratory allergy, taking into account the clinical context that suggested this form of treatment, the recently developed aspects, the future perspectives and unmet needs, This is not, therefore, a systematic review, rather a narrative historical description of the past history, and a look forward to the future opportunities. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

34. EAACI/GA2LEN/EDF guideline: management of urticaria

Author

Zuberbier, T, Bindslev Jensen, C, Canonica, Giorgio, Grattan, Ce, Greaves, Mw, Henz, Bm, Kapp, A, Kozel, Mm, Maurer, M, Merk, Hf, Schäfer, T, Simon, D, Vena, Ga, Wedi, B, and Eaaci/ga2len/edf

Subjects
Male, Pathology, medicine.medical_specialty, Urticaria, Immunology, Risk Assessment, Severity of Illness Index, Drug Administration Schedule, Quality of life, Cyclosporin a, Anti-Allergic Agents, Humans, Immunology and Allergy, Medicine, media_common.cataloged_instance, Physical urticaria, European union, Intensive care medicine, Adverse effect, Life Style, Randomized Controlled Trials as Topic, media_common, Dose-Response Relationship, Drug, business.industry, Guideline, medicine.disease, Combined Modality Therapy, Response to treatment, Diet, First line treatment, Treatment Outcome, Histamine H1 Antagonists, Quality of Life, Female, business, Immunosuppressive Agents, Follow-Up Studies
Abstract

This guideline is the result of a consensus reached during a panel discussion at the second International Consensus Meeting on Urticara, Urticaria 2004, a joint initiative of the EAACI Dermatology Section and GA2LEN. Urticaria has a profound impact on the quality of life, and effective treatment is therefore required. The recommended first line treatment are nonsedating H1 antihistamines. They have proven to be effective in double-blind controlled studies, but dosages increased up to fourfold over the recommended doses may be necessary. However, for different urticaria subtypes and in view of individual variation in the course of the disease and response to treatment, additional or alternative therapies may be required. Immunosuppressive drugs like cyclosporin A and corticosteroids are not recommended for long-term treatment due to unavoidable severe adverse effects. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and formally approved by the European Union of Medical Specialists (UEMS).

Published
2006

35. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria

Author

Zuberbier, T, Bindslev Jensen, C, Canonica, Giorgio, Grattan, Ce, Greaves, Mw, Henz, Bm, Kapp, A, Kozel, Mm, Maurer, M, Merk, Hf, Schäfer, T, Simon, D, Vena, Ga, Wedi, B, and Eaaci/ga2len/edf

Subjects
Hypersensitivity, Immediate, Male, Urticaria, Immunology, Allergens, Sensitivity and Specificity, Severity of Illness Index, Europe, Risk Factors, Prevalence, Humans, Immunology and Allergy, Female, Skin Tests
Abstract

This guideline is the result of a consensus reached during a panel discussion at the 2nd International Consensus Meeting on Urticaria, Urticaria 2004, a joint initiative of the European Academy of Allergology and Clinical Immunology Dermatology Section and the European Union (EU)-funded network of excellence, GA2LEN. It covers the definition and classification of urticaria, taking into account the recent progress in identifying causes, eliciting factors and pathomechanisms of this disease. We have outlined useful diagnostic approaches for different subtypes of urticaria. This guideline was, in addition, accepted by the European Dermatology Forum (EDF) and was formally approved by the European Union of Medical Specialists (UEMS).

Published
2006

36. 2019 ARIA Care pathways for allergen immunotherapy.

Author

Bousquet, Jean, Pfaar, Oliver, Togias, Alkis, Schünemann, Holger J., Ansotegui, Ignacio, Papadopoulos, Nikolaos G., Tsiligianni, Ioanna, Agache, Ioana, Anto, Josep M., Bachert, Claus, Bedbrook, Anna, Bergmann, Karl‐Christian, Bosnic‐Anticevich, Sinthia, Bosse, Isabelle, Brozek, Jan, Calderon, Moises A., Canonica, Giorgio W., Caraballo, Luigi, Cardona, Victoria, and Casale, Thomas

Subjects
MEDICAL personnel, ALLERGENS, IMMUNOTHERAPY, ALLERGENIC extracts, ARIA
Abstract

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence‐based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good‐quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow‐up of patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

37. Ragweed sensitization in Europe - GA(2)LEN study suggests increasing prevalence

Author

Burbach, Gj, Heinzerling, Lm, Röhnelt, C, Bergmann, Kc, Behrendt, H, Zuberbier, T, Galen, Study, and Canonica, Giorgio

Subjects
Ragweed, Adult, Male, Allergy, Immunology, MEDLINE, medicine, Prevalence, Immunology and Allergy, Ambrosia, Humans, Sensitization, Asthma, Skin Tests, biology, business.industry, Rhinitis, Allergic, Seasonal, Middle Aged, medicine.disease, biology.organism_classification, Europe, medicine.anatomical_structure, Multicenter study, Female, business
Abstract

Ambrosia has now reached threshold for high prevalence allergen in Europe.

Published
2009

38. Standards for practical allergen-specific immunotherapy

Author

Alvarez Cuesta, E, Bousquet, J, Canonica, Giorgio, Durham, Sr, Malling, Hj, Valovirta, E, and EAACI Immunotherapy Task Force

Subjects
business.industry, Immunology, Dose-Response Relationship, Immunologic, Specific immunotherapy, Allergens, Reference Standards, Executive committee, Desensitization, Immunologic, Risk Factors, Immunology and Allergy, Medicine, Humans, Immunotherapy, business, Humanities
Abstract

Foreword The paper was drafted by Emilio Alvarez-Cuesta (chairman), Spain, Jean Bousquet, France, G Walter Canonica, Italy, Stephen Durham, England, Hans-Jorgen Mailing, Denmark and Erkka Valovirta, Finland. The paper was revised and input added by a European Reference Group, endorsed by National Societies associated EAACI and approved by the Executive Committee of EAACI. Reference group: U Muller, G Passalacqua, M Jutel, B Niggemann, T Frew, M. Franchi, R Pinto, D Price, K Nekam, P Eigenmann, L Delgado. F Bonifaci and H Mosbeck supervised the venom section.

Published
2006

40. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI) Allergic Rhinitis and its Impact on Asthma (ARIA)

Author

Bousquet, Jean, primary, Cauwenberge, Paul, additional, Bachert, Claus, additional, Canonica, Giorgio W, additional, Demoly, Pascal, additional, Durham, Stephen R, additional, Fokkens, Wystske, additional, Lockey, Richard, additional, Meltzer, Eli O, additional, Mullol, Joaquim, additional, Naclerio, Robert M, additional, Price, David, additional, Simons, F Estelle R, additional, Vignola, Antonio M, additional, and Warner, John O, additional

Published
2003
Full Text
View/download PDF

41. Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID‐19?

Author

Heffler, Enrico, Detoraki, Aikaterini, Contoli, Marco, Papi, Alberto, Paoletti, Giovanni, Malipiero, Giacomo, Brussino, Luisa, Crimi, Claudia, Morrone, Daniela, Padovani, Marianna, Guida, Giuseppe, Gerli, Alberto Giovanni, Centanni, Stefano, Senna, Gianenrico, Paggiaro, Pierluigi, Blasi, Francesco, and Canonica, Giorgio Walter

Subjects
COVID-19, ASTHMATICS, SARS-CoV-2
Abstract

Moreover, Chhiba et al did not found significant difference in risk of hospitalization or mortality due to COVID-19 in patients with or without asthma, even after adjusting for covariates or the level of asthma treatment. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? REFERENCES 1 Kow CS, Capstick T, Hasan SS. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?. [Extracted from the article]

Published
2021
Full Text
View/download PDF

43. Antihistamines in atopic dermatitis.

Author

Ciprandi, Giorgio, Scordamaglia, Antonio, Buscaglia, Sandra, Passalacqua, Giovanni, and Canonica, Giorgio W.

Subjects
ANTIHISTAMINES, ATOPIC dermatitis, ITCHING, THERAPEUTICS, DRUG receptors, PHARMACODYNAMICS, DRUG side effects
Abstract

The article discusses the use of antihistamines in the treatment of atopic dermatitis (AD) and adverse reactions to foods, mainly for the control of such symptoms as itching. Histamine exerts its physiological effects through three different receptors, H1, H2 and H3. Pharmacological research has developed antihistaminic drugs of two classes, anti-H1 receptor blockers and anti-H2 receptor blockers. Anti-H1 receptor drugs are used widely for itching, which is mediated by H1 receptors. According to the experiment presented, anti-H1 monotherapy alone is not suggested. In the absence of side effects, anti-H1 drugs, may be considered to be useful tools in association with other etiopathogenetical treatments.

Published
1989
Full Text
View/download PDF

44. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement

Author

Erik Melén, Edward F Knol, Karin Hoffmann-Sommergruber, N. Khaltaev, Bolesław Samoliński, Cezmi A. Akdis, Claus Bachert, Hui Du, Sinthia Bosnic-Anticevich, Maria Teresa Ventura, Ruby Pawankar, Mohamed H. Shamji, Mübeccel Akdis, Ken Ohta, Joaquim Mullol, Jean Bousquet, Robert M. Naclerio, Ioana Agache, Tari Haahtela, Arunas Valiulis, Sanna Toppila-Salmi, I. J. Ansotegui, J. C. Ivancevich, Oliver Pfaar, Giorgio Walter Canonica, Gabrielle L. Onorato, Ya-dong Gao, Alvaro A. Cruz, Anna Bedbrook, Stefano Del Giacco, Yoshitaka Okamoto, Marek Jutel, P. M. Matricardi, Nikos G Papadopoulos, Wiencyslawa Czarlewski, João Fonseca, D. Larenas-Linnemann, Piotr Kuna, Tomas Chivato, Arzu Yorgancioglu, Jürgen Schwarze, Torsten Zuberbier, Ludger Klimek, Liam O'Mahony, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Poland, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Universitätsmedizin Berlin, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, CharitéHumboldt-Universität zu BerlinBerlin, Germany, University Hospital, Montpellier, France, MACVIA-France, Montpellier, France, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, Transylvania University BrasovBrasov, Romania, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, NSW, Australia, Personalized Medicine Clinic Asthma & Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Rozzano, MI, Italy, School of Medicine, University CEU San PabloMadrid, Spain, ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Montpellier, France, Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital 'Duilio Casula', University of Cagliari, Cagliari, Italy, Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, University of Science and Technology, Wuhan, Hubei, China, Center for research in health technologies and information systems- CINTESIS, Universidade do PortoPorto, Portugal, Allergy Unit, Instituto CUF Porto e Hospital CUF PortoPorto, Portugal, Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do PortoPorto, Portugal, Faculdade de Medicina da Universidade do PortoPorto, Portugal, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Pathophysiology and Allergy Research, Medical University of ViennaVienna, Austria, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Aires, Argentina, Geneva, Switzerland, Departments of Immunology and Dermatology/Allergology, University Medical CenterUtrecht, Netherlands, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and HospitalMéxico City, Mexico, Institute of Environmental Medicine, Karolinska Institutet and Sachs' Children's HospitalStockholm, Sweden, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Johns Hopkins School of Medicine, Baltimore, MD, United States, National Hospital Organization, Tokyo National HospitalTokyo, Japan, Dept of Otorhinolaryngology, Chiba University HospitalChiba, Japan, Departments of Medicine and Microbiology, University College Cork, Cork, Ireland, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of ManchesterManchester, United Kingdom, Department of Pediatrics, Nippon Medical SchoolTokyo, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Germany, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland, Centre for Inflammation Research, Child Life and Health, University of Edinburgh, Edinburgh, United Kingdom, Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London. Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom, University of Bari Medical School, Unit of Geriatric ImmunoallergologyBari, Italy, Vilnius University, Faculty of Medicine, Institute of Clinical Medicine &, Institute of Health SciencesVilnius, Lithuania, European Academy of Paediatrics, Brussels, Belgium, Celal Bayar University, Department of PulmonologyManisa, Turkey, Charité - Universitätsmedizin BerlinBerlin, Germany, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and AllergyBerlin, Germany, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi, Bousquet, Jean, Akdis, Mübeccel, Bachert, Clau, Agache, Ioana, Ansotegui, Ignacio, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Canonica, Giorgio W, Chivato, Toma, Cruz, Alvaro A, Czarlewski, Wiencyslawa, Giacco, Stefano Del, Du, Hui, Fonseca, Joao A, Gao, Yadong, Haahtela, Tari, Hoffmann-Sommergruber, Karin, Ivancevich, Juan-Carlo, Iaccarino, Guido, Khaltaev, Nikolai, Knol, Edward F, Kuna, Piotr, Larenas-Linnemann, Desiree, Melen, Erik, Mullol, Joaquim, Naclerio, Robert, Ohta, Ken, Okamoto, Yoshitaka, O'Mahony, Liam, Onorato, Gabrielle L, Papadopoulos, Nikos G, Pawankar, Ruby, Pfaar, Oliver, Samolinski, Boleslaw, Schwarze, Jurgen, Toppila-Salmi, Sanna, Shamji, Mohamed H, Ventura, Maria Teresa, Valiulis, Aruna, Yorgancioglu, Arzu, Matricardi, Paolo, Zuberbier, Torsten, Department of Dermatology, Allergology and Venereology, HUS Inflammation Center, and Department of Pathology

Subjects
0301 basic medicine, Allergy, Eaaci Position Paper, CD8-Positive T-Lymphocytes, Social life, 0302 clinical medicine, clinical immunotherapy, Pandemic, Immunology and Allergy, Infection control, AIT, Treatment options, 3. Good health, Coronavirus Infections, Allergen immunotherapy, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Immunology, Eaaci Position Papers, MECHANISMS, Betacoronavirus, 03 medical and health sciences, Allergists, Th2 Cells, VACCINES, allergy treatment, medicine, VENOM ALLERGY, Humans, Intensive care medicine, Pandemics, Infection Control, Sublingual Immunotherapy, immunotherapy vaccines and mechanisms, SARS-CoV-2, business.industry, COVID-19, Immunoglobulin E, medicine.disease, Rhinitis, Allergic, Asthma, Allergen-specific immunotherapy, Coronavirus, Eosinophils, 030104 developmental biology, Immunoglobulin M, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, business
Abstract

The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.

Published
2020

45. Real-world biologics response and super-response in the International Severe Asthma Registry cohort.

Author

Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, Martin N, Bergeron C, Al-Ahmad M, Altraja A, Larenas-Linnemann D, Murray R, Celis-Preciado CA, Al-Lehebi R, Belhassen M, Bhutani M, Bosnic-Anticevich SZ, Bourdin A, Brusselle GG, Busby J, Canonica GW, Heffler E, Chapman KR, Charriot J, Christoff GC, Chung LP, Cosio BG, Côté A, Costello RW, Cushen B, Fingleton J, Fonseca JA, Gibson PG, Heaney LG, Huang EW, Iwanaga T, Jackson DJ, Koh MS, Lehtimäki L, Máspero J, Mahboub B, Menzies-Gow AN, Mitchell PD, Papadopoulos NG, Papaioannou AI, Perez-de-Llano L, Perng DW, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Roche N, Sadatsafavi M, Salvi S, Schmid JM, Sheu CC, Sirena C, Torres-Duque CA, Salameh L, Patel PH, Ulrik CS, Wang E, Wechsler ME, and Price DB

Subjects
Humans, Male, Female, Middle Aged, Treatment Outcome, Adult, Cohort Studies, Aged, Asthma drug therapy, Registries, Biological Products therapeutic use, Anti-Asthmatic Agents therapeutic use, Severity of Illness Index
Abstract

Background: Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma., Methods: Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV 1 ) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super-response criteria were: FEV 1 increase by ≥500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day., Results: 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV 1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, ~40-50% of initiators did not meet response criteria., Conclusions: Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria., (© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

46. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model.

Author

Incorvaia C, Al-Ahmad M, Ansotegui IJ, Arasi S, Bachert C, Bos C, Bousquet J, Bozek A, Caimmi D, Calderón MA, Casale T, Custovic A, De Blay F, Demoly P, Devillier P, Didier A, Fiocchi A, Fox AT, Gevaert P, Gomez M, Heffler E, Ilina N, Irani C, Jutel M, Karagiannis E, Klimek L, Kuna P, O'Hehir R, Kurbacheva O, Matricardi PM, Morais-Almeida M, Mosges R, Novak N, Okamoto Y, Panzner P, Papadopoulos NG, Park HS, Passalacqua G, Pawankar R, Pfaar O, Schmid-Grendelmeier P, Scurati S, Tortajada-Girbés M, Vidal C, Virchow JC, Wahn U, Worm M, Zieglmayer P, and Canonica GW

Subjects
Allergens, Desensitization, Immunologic, Genomics, Humans, Hypersensitivity diagnosis, Hypersensitivity therapy, Precision Medicine
Abstract

The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes., (© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Published
2021
Full Text
View/download PDF

47. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).

Author

Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, Eiwegger T, Bedbrook A, Ansotegui IJ, Anto JM, Bachert C, Bateman ED, Bennoor KS, Berghea EC, Bergmann KC, Blain H, Bonini M, Bosnic-Anticevich S, Boulet LP, Brussino L, Buhl R, Camargos P, Canonica GW, Cardona V, Casale T, Chinthrajah S, Akdis M, Chivato T, Christoff G, Cruz AA, Czarlewski W, Del Giacco S, Du H, El-Gamal Y, Fokkens WJ, Fonseca JA, Gao Y, Gaga M, Gemicioglu B, Gotua M, Haahtela T, Halpin D, Hamelmann E, Hoffmann-Sommergruber K, Humbert M, Ilina N, Ivancevich JC, Joos G, Khaitov M, Kirenga B, Knol EF, Ko FW, Koskinen S, Kowalski ML, Kraxner H, Kudlay D, Kuna P, Kupczyk M, Kvedariene V, Abdul Latiff AH, Le LT, Levin M, Larenas-Linnemann D, Louis R, Masjedi MR, Melén E, Mihaltan F, Milenkovic B, Mohammad Y, Morais-Almeida M, Mullol J, Namazova L, Neffen H, Nunes E, O'Byrne P, O'Hehir R, O'Mahony L, Ohta K, Okamoto Y, Onorato GL, Panzner P, Papadopoulos NG, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Pigearias B, Popov TA, Puggioni F, Regateiro FS, Rolla G, Rottem M, Samolinski B, Sastre J, Schwarze J, Sheikh A, Scichilone N, Soto-Quiros M, Soto-Martinez M, Sova M, Nicola S, Stelmach R, Suppli-Ulrik C, Taborda-Barata L, To T, Tomazic PV, Toppila-Salmi S, Tsiligianni I, Usmani O, Valiulis A, Ventura MT, Viegi G, Vontetsianos T, Wang Y, Williams S, Wong GWK, Yorgancioglu A, Zernotti M, Zidarn M, Zuberbier T, and Agache I

Subjects
Angiotensin-Converting Enzyme 2 physiology, Asthma drug therapy, Humans, Asthma complications, COVID-19 etiology, SARS-CoV-2
Published
2021
Full Text
View/download PDF

48. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.

Author

Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, Agache I, Ansotegui I, Bedbrook A, Bosnic-Anticevich S, Canonica GW, Chivato T, Cruz AA, Czarlewski W, Del Giacco S, Du H, Fonseca JA, Gao Y, Haahtela T, Hoffmann-Sommergruber K, Ivancevich JC, Khaltaev N, Knol EF, Kuna P, Larenas-Linnemann D, Melen E, Mullol J, Naclerio R, Ohta K, Okamoto Y, O'Mahony L, Onorato GL, Papadopoulos NG, Pawankar R, Pfaar O, Samolinski B, Schwarze J, Toppila-Salmi S, Shamji MH, Teresa Ventura M, Valiulis A, Yorgancioglu A, Matricardi P, and Zuberbier T

Subjects
Allergists psychology, Asthma complications, CD8-Positive T-Lymphocytes immunology, COVID-19, Coronavirus Infections complications, Coronavirus Infections virology, Eosinophils immunology, Humans, Immunoglobulin E metabolism, Immunoglobulin M metabolism, Pneumonia, Viral complications, Pneumonia, Viral virology, Rhinitis, Allergic complications, SARS-CoV-2, Th2 Cells immunology, Asthma therapy, Betacoronavirus genetics, Betacoronavirus immunology, Coronavirus Infections immunology, Coronavirus Infections prevention & control, Infection Control methods, Pandemics prevention & control, Pneumonia, Viral immunology, Pneumonia, Viral prevention & control, Rhinitis, Allergic therapy, Sublingual Immunotherapy methods
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results